BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
The risk of falling space junk hitting airplanes is on the rise, experts warn - 2NATO official says members often aren't buying weapons together, and it's a mistake
- 3Doggie diversity in size and shape began at least 11,000 years ago
- 4Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- 5The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- France will build a new aircraft carrier as it increases defense spending
- Top 15 Style Creators Changing the Business
- Iran denies launching ballistic missiles towards Kurdistan region of Iraq
- UNICEF: More than 100 children killed in Gaza since ceasefire
- Netflix is releasing a documentary on Elizabeth Smart. What to know about her kidnapping, rescue and where she is now.
- Four new luxury hotel openings in Italy you need to know about
- Solid Living Tips: Experiences from a Wellness Fan
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
